Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GRN 300

Next Previous
Drug Profile

GRN 300

Alternative Names: ARN-3261; GRN-300

Latest Information Update: 15 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrien Pharmaceuticals
  • Developer Arrien Pharmaceuticals; Green3Bio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Salt-inducible kinase-2 inhibitors; SIK3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Ovarian cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 17 Apr 2026 Pharmacodynamics data from a preclinical in Ovarian-cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 11 Apr 2025 GRN 300 is still in phase I development for Ovarian cancer in USA (Greenfire Bio pipeline, April 2025)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top